Outcomes Study of MTM in a Medicare ACO

NCT02875925 | Completed

• 1 other identifier: MSSMMTM1
• Study Type: interventional
• Target: 77
• Locations: 1 country
• Sites: 1

Brief Summary

This is a non-randomized, prospective, quasi-experimental study designed to assess the impact of pharmacist-provided medication management on total cost of care and clinical outcomes (ie, hospitalizations, emergency department visits) in a real-world clinical practice.

Conditions

Pain; Hypoglycemia

Keywords

blood coagulation

Outcome Measures

Primary Outcomes (2)

• Hospitalization Rates

  12 months

• Emergency Department Visits

  12 months

Study Arms (2)

MTM

EXPERIMENTAL

Patients will receive MTM at an individualized frequency for 1 year.

Other: MTM

Control

NO INTERVENTION

Patients enrolled in the control group will not experience any change in their medical care.

Interventions

MTM OTHER

Medication management is a process that ensures each patient's medications are assessed to determine the appropriateness, effectiveness, safety, and convenience of each medication for the patient. Medication management is fully integrated with the care team. Pharmacists provide this service to identify, prevent, and resolve drug therapy problems improve outcomes.

Also known as: Medication Management

MTM

Eligibility Criteria

• Age: 66 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Older Adult (65+)

You may qualify if:

• MSSP patient, attributed to Community Health Network
• Receive primary care at HealthEast as demonstrated by having \> 2 outpatient visits at one of HealthEast's primary care clinics in the 3 years prior to enrollment.
• Currently taking \> 1 medication from the following therapeutic classes: antiplatelet/anticoagulant, hypoglycemic (oral or insulin), opioid analgesic
• Willingness of subject to work with a MTM pharmacist for medication management throughout the 12 month study period.
• Provided written informed consent

You may not qualify if:

• Currently receiving their primary care at a non-HealthEast clinic
• Inpatient status at Bethesda Hospital within last 12 months
• Currently receiving hospice care
• In the opinion of the investigator, have any kind of disorder that may compromise the ability of the subject to provide written informed consent

Sponsors & Collaborators

• HealthEast Care System: lead
• University of Minnesota: collaborator

Study Sites (1)

HealthEast Care System

Saint Paul, Minnesota, 55103, United States

Location

MeSH Terms

Conditions

Pain; Hypoglycemia; Thrombosis

Interventions

Medication Therapy Management

Condition Hierarchy (Ancestors)

Neurologic Manifestations; Signs and Symptoms; Pathological Conditions, Signs and Symptoms; Glucose Metabolism Disorders; Metabolic Diseases; Nutritional and Metabolic Diseases; Embolism and Thrombosis; Vascular Diseases; Cardiovascular Diseases

Intervention Hierarchy (Ancestors)

Pharmaceutical Services; Health Services; Health Care Facilities Workforce and Services; Medicare Part D; Insurance, Pharmaceutical Services; Insurance, Health; Insurance; Financing, Organized; Economics; Health Care Economics and Organizations; Medicare; Patient Care Management; Health Services Administration

Study Officials

• Margaret Wallace, PharmD, MS

  HealthEast Care System

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: HEALTH SERVICES RESEARCH
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: August 15, 2016
• First Posted: August 23, 2016
• Study Start: December 1, 2015
• Primary Completion: December 1, 2017
• Study Completion: December 1, 2017
• Last Updated: February 27, 2018

Record last verified: 2017-06

Data Sharing

• IPD Sharing: Will share

Locations

US (1)